FDA calendar · September 2023 · built from SEC filings

PDUFA dates September 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

1 PDUFA date fell in September 2023: GSK (Sep 2023). The FDA calendar also recorded 38 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in September 2023

1 PDUFA target action date in September 2023, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
Sep 2023GSK plcGSKNot namedSEC Form 8-K, filed 2025-02-05

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

September 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Sep 2023Month disclosedSKYCLARYS® (omaveloxolone)BIIBFDA approval—ApprovedSEC Form 10-K
Sep 2023Month disclosedLYMPHIRCTORComplete Response Letter—CRL issuedSEC Form 10-K
Sep 2023Month disclosedvascularHUMANDA/BLA submission—CompletedSEC Form 10-Q
Sep 2023Month disclosedRYZUMVIIRDFDA approval—Approvedsec_424b
Sep 2023Month disclosedVOQUEZNA® (vonoprazan)PHATNDA/BLA submission—CompletedSEC Form 10-Q
Sep 2023Month disclosedPUR3100PULMNDA/BLA accepted—CompletedSEC Form 10-Q
Sep 2023Month disclosed—RCKTComplete Response Lettersevere LAD-ICRL issuedsec_424b
Sep 2023Month disclosedTaliciaRDHLLabel expansion—ApprovedSEC Form 10-K
September 6, 2023IBRANCE® (palbociclib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
September 7, 2023Xalkori (crizotinib)PFEFDA approval—ApprovedopenFDA Drugs@FDA
September 7, 2023Xalkori (crizotinib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
September 8, 2023APHEXDA® (motixafortide)BLRXFDA approvalmultiple myelomaApprovedSEC 8-K Exhibit 99.1
September 13, 2023ONPATTRO® (patisiran)ALNYAdvisory committee—PositiveFDA advisory committee calendar
September 14, 2023Temodar (temozolomide)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
September 15, 2023OJJAARA (momelotinib)GSKFDA approvalTo treat intermediate or high-risk myelofibrosis in adults with anemiaApprovedFDA Novel Drug Approvals
September 15, 2023Nexviazyme (avalglucosidase alfa-ngpt)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
September 19, 2023—SPRYComplete Response Letter—CRL issuedSEC Form 10-K
September 19, 2023Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate)SPRYComplete Response Letter—CRL issuedFDA Complete Response Letters
September 22, 2023NurOwn (debamestrocel)BCLINDA/BLA submissionmild to moderate ALSCompletedsec_s1
September 26, 2023Bosulif (bosutinib monohydrate)PFEFDA approval—ApprovedopenFDA Drugs@FDA
September 26, 2023Bosulif (bosutinib monohydrate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
September 27, 2023Entyvio® (vedolizumab)TAKFDA approval—ApprovedopenFDA Drugs@FDA
September 28, 2023Ebglyss (lebrikizumab-lbkz)LLYComplete Response Letter—CRL issuedFDA Complete Response Letters
September 29, 2023Micafungin In Sodium Chloride 0.9% (micafungin sodium)BAXFDA approval—ApprovedopenFDA Drugs@FDA
September 29, 2023Vasopressin In Sodium Chloride 0.9% (vasopressin)BAXFDA approval—ApprovedopenFDA Drugs@FDA
September 29, 2023Tofidence (tocilizumab-bavi)BIIBFDA approval—ApprovedopenFDA Drugs@FDA
September 29, 2023Rivfloza (nedosiran sodium)NVOFDA approval—ApprovedFDA Novel Drug Approvals
September 30, 2023—TARSFDA approval—ApprovedSEC Form 10-Q

September 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Sep 2023Month disclosedzilebesiranALNYTopline readout—PositiveSEC Form 10-Q
Sep 2023Month disclosed—ARQTTopline readout—PositiveSEC Form 10-K
Sep 2023Month disclosedvascularHUMATopline readout—PositiveSEC Form 10-Q
Sep 2023Month disclosedazithromycinINSMTopline readout—PositiveSEC 8-K Exhibit 99.1
Sep 2023Month disclosed—VALNTopline readout—PositiveSEC Form 10-K

September 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Sep 2023Month disclosedKOSTAIVEARCTTrial start—CompletedSEC Form 10-K
Sep 2023Month disclosedAPHEXDA® (motixafortide)BLRXTrial start—CompletedSEC 8-K Exhibit 99.1
Sep 2023Month disclosedVK2735VKTXTrial startobesityCompletedsec_424b
September 20, 2023LB-100NMADTrial startovarian clear cell carcinomaCompletedsec_424b
Sep 2023Month disclosedprostate (APVO442)KAPATrial start—Completedsec_s1

Questions

What PDUFA dates are in September 2023?

1 PDUFA date fell in September 2023: GSK (Sep 2023). The FDA calendar also recorded 38 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.